ArticleBMC oral health2026
Topical 0.02% mitomycin in postoperative healing of oral submucous fibrosis treated with fibrous band release and buccal fat pad reconstruction: a pilot split-mouth study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTopical application of 0.02% Mitomycin-C (MMC) has demonstrated efficacy in reducing fibrosis in ophthalmic and laryngeal procedures. This pilot study aimed to evaluate the potential role of MMC in enhancing healing outcomes in patients with Oral Submucous Fibrosis (OSMF) following surgical release of fibrous bands and reconstruction with the Buccal Fat Pad (BFP). METHODOLOGY: A prospective, double-blinded, split-mouth feasibility pilot study was conducted on 10 patients diagnosed with OSMF. Each patient underwent surgical release of fibrous bands and/or coronoidectomy under general anaesthesia, followed by BFP reconstruction bilaterally. The right buccal mucosa (study side) received topical application of 0.02% MMC (0.2 mg/ml) twice, first, for 5 min over the raw surgical site before BFP placement, and again after 10 days for 3 min over the healing mucosa. The left side (control) received a placebo (normal saline) following the same protocol. Patients were assessed over three months for mucosal pliability, cheek flexibility, mucosal colouration and mouth opening.
resultsHowever, despite the theoretical antifibrotic potential of MMC, no statistically significant difference was observed between the MMC-treated and control sides with respect to mucosal pliability or cheek flexibility at any postoperative interval. Although preoperative cheek flexibility (4 ± 0.67 mm) demonstrated initial postoperative improvement, this was not sustained during follow-up, and the MMC application did not confer any measurable long-term advantage over placebo. Additionally, mucosal coloration remained stable and comparable on both sides, indicating no clinically discernible enhancement in mucosal healing attributable to MMC. Notably, no adverse tissue reactions or complications were associated with MMC use, supporting its local biocompatibility. Postoperative mouth opening showed significant improvement from a baseline of 16 ± 2.79 mm to 38.4 ± 1.58 mm at 1 week (T1), 36.1 ± 1.85 mm at 1 month (T2), and 33 ± 2.11 mm at 3 months (T3).
conclusionThese findings suggest that while MMC is safe for intraoral application at this concentration, its therapeutic efficacy in mitigating fibrosis in the OSMF surgical site remains inconclusive, warranting further investigation through larger, controlled trials.
trial registrationClinical Trials Registry- India registration (CTRI/2022/04/041738) dated 08/04/2022).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.